Generative Artificial Intelligence and Predictive Analytics in Clinical Data Management: A Review of the Emerging Applications to Study Protocol Development and Case Report Form Design
Journal of the Society for Clinical Data Management · 2026-10-28 · 0 (1)
DOI: 10.47912/jscdm.499 ↗Abstract
ABSTRACT Background: Clinical trial operations incur substantial costs from two preventable sources: protocol amendments — which affect more than 40% of studies and average $450,000 each in remediation expense — and Case Report Form (CRF) design deficiencies, which contribute to high data-query rates and prolonged database-lock timelines. Generative artificial intelligence (GenAI) and predictive analytics have attracted growing industry interest as tools that could address both problems systematically. Objectives: This review examines how GenAI and predictive analytics are currently being applied to clinical study protocol authoring, eligibility criteria optimisation, CRF design, and CDISC-compliance mapping; evaluates the evidence for operational improvement; and identifies unresolved technical, regulatory, and ethical challenges. Methods: A narrative synthesis was conducted using peer-reviewed literature (PubMed, Embase, Scopus, IEEE Xplore; 2019–2025), regulatory guidance documents (FDA, EMA, ICH), and relevant grey literature. Sources were assessed for methodological transparency and relevance to clinical data management practice. Results: Domain-adapted large language models reduced protocol authoring time by 30–45% and lowered first-draft amendment rates by up to 28% in reported implementations. AI-assisted CRF generation cut form-build timelines from weeks to under 72 hours and reduced data-query rates by 22–35%. Predictive analytics models demonstrated approximately 85% accuracy in prospective enrollment forecasting, and digital twin approaches provided statistical efficiency equivalent to a 25% sample-size reduction in selected Phase II scenarios. Conclusions: Evidence supports meaningful operational gains from AI integration in clinical data management workflows; however, prospective controlled evaluations remain scarce. Hallucination mitigation, bias-aware model governance, and alignment with evolving FDA and EMA guidance are prerequisites for responsible adoption.
EUVIMED